FFO
CRVS icon

Fortitude Family Office’s Corvus Pharmaceuticals CRVS Stock Holding History

Fortitude Family Office’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.45K Buy
+99
New +$1.58K ﹤0.01% 1396

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fortitude Family Office's CRVS Position: Q1 2026 in Review

Fortitude Family Office opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 99 shares worth $1.45K. The stake represents ﹤0.01% of the portfolio and ranks #1396 among its holdings.

164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Fortitude Family Office held 99 shares of Corvus Pharmaceuticals worth $1.45K as of Q1 2026.
  • Corvus Pharmaceuticals was a new Fortitude Family Office position in Q1 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1396 holding.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.